Last reviewed · How we verify
iSGLT2
At a glance
| Generic name | iSGLT2 |
|---|---|
| Also known as | SGLT2 inhibitor |
| Sponsor | Maximo Agustin Schiavone |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 (PHASE4)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
- ISGLT2 in Patients Without DM With Acute MI
- Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial (NA)
- Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study (PHASE2)
- Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study (PHASE4)
- Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iSGLT2 CI brief — competitive landscape report
- iSGLT2 updates RSS · CI watch RSS
- Maximo Agustin Schiavone portfolio CI